Trial Profile

A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allergic rhinitis/rhinoconjunctivitis (ARC) caused by house dust mite (HDM) allergy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs House dust mite allergy immunotherapy subcutaneous HAL Allergy (Primary)
Indications Allergic rhinitis; Allergic rhinoconjunctivitis
Focus Registrational; Therapeutic Use
Sponsors HAL Allergy

11 Apr 2019 Status changed from recruiting to completed.
11 Apr 2019 This trial has been completed in Portugal, according to European Clinical Trials Database.
04 Jul 2018 This trial was completed in Slovakia (2018-04-23), according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com